Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October 2018. Because it competes with three previously approved anti-IL-5 agents (GlaxoSmithKline’s Nucala, Teva’s Cinqair, and AstraZeneca’s Fasenra) for the eosinophilic asthma patient population and with an anti-IgE agent Xolair (Roche) for a subset of severe allergic and eosinophilic asthmatics, physician assessment of Dupixent’s performance will provide Sanofi and Regeneron, their competitors, and companies developing therapies targeting severe asthma with insight regarding its market uptake.

This Emerging Therapies series tracks the awareness, trial, and use of Dupixent for asthma by U.S. pulmonologists and allergists over a year’s time. Additionally, the series examines physician-anticipated trends in asthma treatment, particularly Dupixent’s uptake, and assesses Sanofi and Regeneron’s promotional efforts.


  • What are U.S. pulmonologists and allergists’ awareness of, familiarity with, and perceptions of Dupixent?
  • Among prescribers of Dupixent, to which patients are they prescribing it, what are the reasons for prescribing it, and how satisfied are they with Dupixent?
  • How do prescribers and nonprescribers compare across key metrics?
  • How do the trial and adoption of Dupixent compare with other recent products for asthma?


  • United States

Primary Research

  • Survey of approximately 75 U.S. pulmonologists and allergists for each wave

Key Metrics Included

  • Unaided and aided awareness of Dupixent
  • Familiarity with and impressions of Dupixent
  • Prescriber and nonprescriber profiles
  • Willingness to prescribe Dupixent
  • Performance of Dupixent on key attributes
  • Sales representative visit frequency, reach, and effectiveness
  • Benchmarking against previously launched agents


Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.

Table of contents

  • Asthma - Emerging Therapies - Dupixent (Dupilumab) (US) Wave 3
    • Asthma Emerging Therapies Dupixent (Dupilumab) US Wave 3 (December 2019)

Author(s): Mohit Nasa, MBA; Shubhendu Ghosh, PhD

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.

He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.

Shubhendu Ghosh, Ph.D., is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma.

Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his Ph.D. in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.

Related Reports

Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)

The asthma market in the EU5 is highly competitive. Ma...

View Details

Asthma - Landscape & Forecast - Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

View Details

Asthma - Unmet Need - Detailed, Expanded Analysis (Severe Asthma)

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the entry of

View Details